InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
heyitsmeagain Free
06/09/23 6:19 AM
profile icon
conix Free
05/09/22 6:23 PM
profile icon
MotionOffense78 Free
12/12/20 3:04 PM
profile icon
MotionOffense78 Free
11/09/20 1:39 PM
profile icon
candeloro Free
08/31/20 2:27 PM
profile icon
candeloro Free
08/27/20 4:05 PM
profile icon
candeloro Free
08/27/20 3:55 PM
profile icon
mick Grandfathered
08/27/20 3:50 PM
profile icon
candeloro Free
08/27/20 3:46 PM
profile icon
mick Grandfathered
08/08/20 5:45 PM
profile icon
Rogerthat1 Free
08/08/20 5:24 PM
profile icon
mick Grandfathered
08/05/20 10:39 AM
profile icon
mick Grandfathered
07/29/20 9:40 PM
profile icon
mick Grandfathered
07/29/20 9:38 PM
profile icon
mick Grandfathered
07/29/20 9:36 PM
profile icon
mick Grandfathered
07/29/20 9:33 PM
profile icon
mick Grandfathered
07/29/20 9:33 PM
profile icon
Ablivious Free
07/29/20 9:55 AM
profile icon
BrazenBull Free
07/29/20 1:09 AM
profile icon
Rogerthat1 Free
07/28/20 12:37 AM
profile icon
Rogerthat1 Free
07/27/20 10:01 PM
profile icon
mick Grandfathered
07/27/20 5:05 PM
profile icon
MotionOffense78 Free
07/27/20 4:55 PM
profile icon
mick Grandfathered
07/27/20 12:51 PM
profile icon
mick Grandfathered
07/25/20 8:34 PM
profile icon
mick Grandfathered
07/25/20 8:33 PM
profile icon
mick Grandfathered
07/25/20 8:30 PM
profile icon
mick Grandfathered
07/25/20 8:29 PM
profile icon
Rogerthat1 Free
07/25/20 8:24 PM
profile icon
mick Grandfathered
07/25/20 8:20 PM
profile icon
mick Grandfathered
07/25/20 8:09 PM
profile icon
Rogerthat1 Free
07/25/20 8:02 PM
profile icon
mick Grandfathered
07/25/20 7:59 PM
profile icon
mick Grandfathered
07/25/20 7:57 PM
profile icon
Rogerthat1 Free
07/25/20 6:47 PM
profile icon
mick Grandfathered
07/25/20 2:18 PM
profile icon
mick Grandfathered
07/24/20 11:28 AM
profile icon
mick Grandfathered
07/24/20 11:25 AM
profile icon
mick Grandfathered
07/24/20 11:23 AM
profile icon
mick Grandfathered
07/21/20 4:18 PM
profile icon
mick Grandfathered
07/21/20 2:15 PM
profile icon
mick Grandfathered
07/21/20 12:56 PM
profile icon
MotionOffense78 Free
07/21/20 12:04 PM
profile icon
mick Grandfathered
07/21/20 11:41 AM

Akari Therapeutics (AKTX) RSS Feed

Followers
13
Posters
86
Posts (Today)
0
Posts (Total)
547
Created
09/21/15
Type
Free
Moderators



https://www.akaritx.com/

Akari is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, and leukotriene system,
for the treatment of rare and orphan diseases with unmet need. We believe that blocking early mediators of inflammation
will prevent initiation and continual amplification of the processes that cause certain diseases.

Nomacopan is a recombinant small protein (16,740 Da) that acts on complement component-C5,
preventing release of C5a and formation of C5b–9 (also known as the membrane attack complex, or MAC),
and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response.

Nomacopan is currently being clinically evaluated in four indications:

  • bullous pemphigoid (BP), , a severe blistering skin disease
    atopic keratoconjunctivitis (AKC), a sight threatening surface of the eye condition
    thrombotic microangiopathys (TMA) including including atypical hemolytic uremic syndrome (aHUS) and hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT TMA)
    paroxysmal nocturnal hemoglobinuria (PNH).

Akari believes that the dual action of nomacopan on both C5 and LTB4 may be beneficial in AKC, BP, and aHUS. Akari is also developing other tick derived proteins, including longer acting versions.

Nomacopan is a highly soluble and stable biological molecule, and independently binds to both C5 and LTB4.  This novel dual binding enables targeting of two distinct and separate disease categories based on their underlying etiology.

Four Primary/Lead Indications in Phase II/III Plus Pipeline of Earlier-Stage Targets



https://www.akaritx.com/bullous-pemphigoid-phase-iia/
https://www.akaritx.com/akc-phase-i-ii/
https://www.akaritx.com/long-term-safety/
https://www.akaritx.com/phn-phase-ii-iii/






RECENT PRESS RELEASES

Akari Therapeutics Announces Appointment of Chief Financial Officer

July 1, 2020

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC

July 1, 2020

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2020

June 1, 2020

Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

May 1, 2020

Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

March 31, 2020






https://finance.yahoo.com/news/akari-therapeutics-reports-first-quarter-110010702.html

Patients with COVID-19 pneumonia

  • The Company believes nomacopan’s dual inhibition of both the complement (C5) and leukotriene (LTB4) pathways makes
    the drug potentially well suited for the treatment of patients with COVID-19 pneumonia and related COVID disease.
    Leukotriene inhibition is a validated pathway for the treatment of severe lung inflammation and LTB4 is a potent granulocyte and
    leukocyte attractant which in turn are key drivers of the damaging cytokine storm that underpins acute respiratory distress syndrome (ARDS).
    Likewise, there is growing evidence of the role of the complement pathway in the microthrombi and organ damage associated with COVID-19 pneumonia.
     
    In pre-clinical lung inflammation models including a study of viral induced lung inflammation, nomacopan (formerly known as Coversin)
    showed significant reductions in key lung inflammatory markers such as neutrophils and lung vascular leakage (Garcia et al., 2013; Roversi et al., 2013).
    Likewise in sepsis models (Huber-Lang et al., 2014) nomacopan has shown significant downregulation of a wide range of pro-inflammatory cytokines
    and chemokines including TNF, IL-6, GM-CSF, IL1alpha, IL1beta, IL17, MCP1 (CCL2), MIP1alpha (CCL3),
    MIP1beta (CCL4) which have all been shown to be elevated in patients with COVID-19 disease.
     
    Akari is actively pursuing several clinical study opportunities in patients with COVID-19 pneumonia in the UK and U.S.
    The Company intends to provide additional detail when these programs are finalized and approved.

https://finviz.com/quote.ashx?t=aktx&ty=c&ta=1&p=d




$AKTX FIVE YR.



https://www.otcmarkets.com/stock/AKTX/disclosure

https://www.otcmarkets.com/stock/AKTX/news

https://www.otcmarkets.com/stock/AKTX/security

https://www.otcmarkets.com/stock/AKTX/profile

https://www.otcmarkets.com/stock/AKTX/quote

https://www.otcmarkets.com/stock/AKTX/overview





 *DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post